Harrow (HROW) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Harrow (HROW) over the past year, gaining 104.5% versus a loss of 26.9%. Over five years, KNSA leads with a +580.9% price change compared with +209.6% for HROW. Kiniksa Pharmaceuticals International is the larger company by market cap ($5.99 billion vs $1.14 billion), about 5.2 times the size.
On valuation, Harrow trades at a lower forward P/E (11.0x vs 47.5x for Kiniksa Pharmaceuticals International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | KNSA |
|---|---|---|
| Share price | $30.48 | $76.82 |
| Market cap | $1.14B | $5.99B |
| 1-day change | -0.46% | -1.47% |
| YTD return | -37.51% | +88.99% |
| 1-year return | -26.92% | +104.51% |
| 5-year return | +209.61% | +580.87% |
| P/E ratio (TTM) | — | 77.59 |
| Forward P/E | 10.99 | 47.49 |
| EPS (TTM) | $-0.99 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | — | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $54.85 | $82.94 |
| 52-week low | $28.54 | $35.20 |
| Distance from 52-week high | -44.43% | -7.38% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.25% | +27.58% |
| Average volume | 555.14K | 578.96K |
| Shares outstanding | 37.49M | 48.29M |
| Employees | 373 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kiniksa Pharmaceuticals International is about 5.2 times larger than Harrow by market value ($5.99B vs $1.14B).
- KNSA has outperformed HROW by 131.4 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
HROW vs KNSA FAQ
Which is bigger, Harrow or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $5.99B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, HROW or KNSA?
KNSA returned +104.51% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.